KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Gross Margin (2016 - 2026)

Neogenomics filings provide 17 years of Gross Margin readings, the most recent being 43.32% for Q1 2026.

  • On a quarterly basis, Gross Margin fell 27.0% to 43.32% in Q1 2026 year-over-year; TTM through Mar 2026 was 43.15%, a 115.0% decrease, with the full-year FY2025 number at 43.21%, down 71.0% from a year prior.
  • Gross Margin hit 43.32% in Q1 2026 for Neogenomics, down from 43.83% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 44.92% in Q4 2024 to a low of 32.63% in Q1 2022.
  • Median Gross Margin over the past 5 years was 42.61% (2025), compared with a mean of 41.39%.
  • Biggest five-year swings in Gross Margin: plummeted -840bps in 2022 and later surged 732bps in 2023.
  • Neogenomics' Gross Margin stood at 40.97% in 2022, then rose by 6bps to 43.45% in 2023, then grew by 3bps to 44.92% in 2024, then fell by -2bps to 43.83% in 2025, then decreased by -1bps to 43.32% in 2026.
  • The last three reported values for Gross Margin were 43.32% (Q1 2026), 43.83% (Q4 2025), and 42.84% (Q3 2025) per Business Quant data.